Biohaven Pharma (BHVN) Tops Q2 EPS by 31c

Biohaven Pharma (NYSE: BHVN) reported Q2 EPS of ($1.63), $0.31 better than the analyst estimate of ($1.94).

For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.

You May Also Be Interested In

• Iran Has Resumed Producing Ballistic Missiles, U.S. and Middle East Officials Say - WSJ
• Active options: AAPL NVDA TSLA SPCX MU META INTC ORCL GOOGL AMZN PLTR
• Crude Inventory 0.4M Barrels Last Week - EIA